331 related articles for article (PubMed ID: 12437652)
1. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study.
Farge D; Marolleau JP; Zohar S; Marjanovic Z; Cabane J; Mounier N; Hachulla E; Philippe P; Sibilia J; Rabian C; Chevret S; Gluckman E;
Br J Haematol; 2002 Dec; 119(3):726-39. PubMed ID: 12437652
[TBL] [Abstract][Full Text] [Related]
2. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan.
Ayano M; Tsukamoto H; Mitoma H; Kimoto Y; Akahoshi M; Arinobu Y; Miyamoto T; Horiuchi T; Niiro H; Nagafuji K; Harada M; Akashi K
Arthritis Res Ther; 2019 Jan; 21(1):30. PubMed ID: 30670057
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis.
Vonk MC; Marjanovic Z; van den Hoogen FH; Zohar S; Schattenberg AV; Fibbe WE; Larghero J; Gluckman E; Preijers FW; van Dijk AP; Bax JJ; Roblot P; van Riel PL; van Laar JM; Farge D
Ann Rheum Dis; 2008 Jan; 67(1):98-104. PubMed ID: 17526554
[TBL] [Abstract][Full Text] [Related]
4. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease.
Tsukamoto H; Nagafuji K; Horiuchi T; Miyamoto T; Aoki K; Takase K; Henzan H; Himeji D; Koyama T; Miyake K; Inoue Y; Nakashima H; Otsuka T; Tanaka Y; Nagasawa K; Harada M
Ann Rheum Dis; 2006 Apr; 65(4):508-14. PubMed ID: 16126798
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.
Binks M; Passweg JR; Furst D; McSweeney P; Sullivan K; Besenthal C; Finke J; Peter HH; van Laar J; Breedveld FC; Fibbe WE; Farge D; Gluckman E; Locatelli F; Martini A; van den Hoogen F; van de Putte L; Schattenberg AV; Arnold R; Bacon PA; Emery P; Espigado I; Hertenstein B; Hiepe F; Kashyap A; Kötter I; Marmont A; Martinez A; Pascual MJ; Gratwohl A; Prentice HG; Black C; Tyndall A
Ann Rheum Dis; 2001 Jun; 60(6):577-84. PubMed ID: 11350846
[TBL] [Abstract][Full Text] [Related]
6. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation.
Burt RK; Traynor AE; Pope R; Schroeder J; Cohen B; Karlin KH; Lobeck L; Goolsby C; Rowlings P; Davis FA; Stefoski D; Terry C; Keever-Taylor C; Rosen S; Vesole D; Fishman M; Brush M; Mujias S; Villa M; Burns WH
Blood; 1998 Nov; 92(10):3505-14. PubMed ID: 9808541
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
8. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?
Vellenga E; van Putten WL; Boogaerts MA; Daenen SM; Verhoef GE; Hagenbeek A; Jonkhoff AR; Huijgens PC; Verdonck LF; van der Lelie J; Schouten HC; Gmür J; Wijermans P; Gratwohl A; Hess U; Fey MF; Löwenberg B
Bone Marrow Transplant; 1999 Jun; 23(12):1279-82. PubMed ID: 10414916
[TBL] [Abstract][Full Text] [Related]
10. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization.
Watts MJ; Sullivan AM; Leverett D; Peniket AJ; Perry AR; Williams CD; Devereux S; Goldstone AH; Linch DC
J Clin Oncol; 1998 Apr; 16(4):1554-60. PubMed ID: 9552065
[TBL] [Abstract][Full Text] [Related]
11. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
Awedan AA
Ann Transplant; 2002; 7(2):38-43. PubMed ID: 12416471
[TBL] [Abstract][Full Text] [Related]
12. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
13. Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma.
Lemoli RM; Fortuna A; Raspadori D; Ventura MA; Martinelli G; Gozzetti A; Leopardi G; Ratta M; Cavo M; Tura S
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():1-11. PubMed ID: 9570675
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
15. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
16. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
17. Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells.
Tsukamoto H; Nagafuji K; Horiuchi T; Mitoma H; Niiro H; Arinobu Y; Inoue Y; To K; Miyamoto T; Iwasaki H; Teshima T; Harada M; Akashi K
Rheumatology (Oxford); 2011 May; 50(5):944-52. PubMed ID: 21172925
[TBL] [Abstract][Full Text] [Related]
18. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
[TBL] [Abstract][Full Text] [Related]
19. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
Kasow KA; Sims-Poston L; Eldridge P; Hale GA
Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
[TBL] [Abstract][Full Text] [Related]
20. Immunological reconstitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression.
Bohgaki T; Atsumi T; Bohgaki M; Furusaki A; Kondo M; Sato-Matsumura KC; Abe R; Kataoka H; Horita T; Yasuda S; Amasaki Y; Nishio M; Sawada K; Shimizu H; Koike T
J Rheumatol; 2009 Jun; 36(6):1240-8. PubMed ID: 19447934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
